Effects of polymers on the drug solubility and dissolution enhancement of poorly water-soluble rivaroxaban
The purpose of this study was to investigate the efficacy of hydrophilic polymers in a solid
dispersion formulation in improving the solubility and dissolution rate of rivaroxaban (RXB) …
dispersion formulation in improving the solubility and dissolution rate of rivaroxaban (RXB) …
[HTML][HTML] Preparation, characterization, and pharmacokinetics of rivaroxaban cocrystals with enhanced in vitro and in vivo properties in beagle dogs
Y Meng, F Tan, J Yao, Y Cui, Y Feng, Z Li… - International Journal of …, 2022 - Elsevier
Rivaroxaban (RIV) is a direct Factor Xa inhibitor anticoagulant, but the oral bioavailability of
RIV is estimated to be only 60% due to its poor solubility. The aim of the present study was to …
RIV is estimated to be only 60% due to its poor solubility. The aim of the present study was to …
Explaining dissolution properties of rivaroxaban cocrystals
E Hriňová, E Skořepová, I Čerňa, J Královičová… - International Journal of …, 2022 - Elsevier
The aim of this study was to improve rivaroxaban water-solubility by cocrystal preparation
and to understand this process. The screening with water-soluble coformers was performed …
and to understand this process. The screening with water-soluble coformers was performed …
Modeling of the Aqueous Solubility of N-butyl-N-methyl-1-phenylpyrrolo [1, 2-a] pyrazine-3-carboxamide: From Micronization to Creation of Amorphous–Crystalline …
VB Markeev, SV Tishkov, AM Vorobei, OO Parenago… - Polymers, 2023 - mdpi.com
N-butyl-N-methyl-1-phenylpyrrole [1, 2-a] pyrazine-3-carboxamide (GML-3) is a potential
candidate for combination drug therapy due to its anxiolytic and antidepressant activity. The …
candidate for combination drug therapy due to its anxiolytic and antidepressant activity. The …
Biopharmaceutics considerations for direct oral anticoagulants
RP de Andrade, TG Caldeira, BV Vasques… - Drug Development …, 2021 - Taylor & Francis
Vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) have been clinically
used in the treatment of coagulation disorders. There are four DOACs approved since 2010 …
used in the treatment of coagulation disorders. There are four DOACs approved since 2010 …